Cure8 research brief
This case shows that upadacitinib, a JAK inhibitor used for refractory IBD, can cause severe anemia in rare cases but that dose reduction (rather than permanent discontinuation) may reversibly restore blood counts while maintaining disease control.
It highlights the need for blood monitoring and shared decision-making when treatment options are limited.
Adults with Crohn's disease considering or taking JAK inhibitors (upadacitinib), clinicians managing multi‑refractory IBD, and patients with limited remaining treatment options.
A published case report describes a 45-year-old woman with multi-refractory Crohn’s disease who achieved rapid clinical and endoscopic response on upadacitinib (45 mg daily) but developed grade 3 normocytic anemia (hemoglobin ~80 g/L) after ~4 months.
The patient elected to continue therapy because of substantial symptomatic benefit; dose adjustments were made and hemoglobin gradually normalized while remission and mucosal healing persisted. The report emphasizes shared decision-making and regular hematologic monitoring during JAK inhibitor therapy.
This brief is based on the article abstract from the journal Gastroenterologie a hepatologie (structured content depth: abstract). Cure8 has summarized the abstract text and has not reviewed additional unpublished data or the full article beyond the supplied extraction.
The summary is based on the article abstract (structured content depth: abstract). Case reports describe a single patient and cannot establish typical risks or outcomes; clinicians should interpret this alongside larger safety data and regulatory guidance. Regular blood tests are recommended for patients on JAK inhibitors.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study reports that upadacitinib produced clinical responses and steroid-free remission in a majority of patients with refractory Crohn's disease at 12 weeks, which may be relevant for people who have not responded...
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...
This study suggests acne is a common real-world side effect of upadacitinib for IBD and can affect treatment decisions and quality of life, especially for younger patients.
